Mustafa ESASSOLAK, Kerem ÖZTÜRK, Fatma SERT

Radiotherapy for Elderly Patients Diagnosed with Laryngeal Carcinoma: A Single Center Experience

OBJECTIVETo evaluate the efficacy and toxicity of definitive and postoperative radiotherapy (RT) for laryngealcarcinoma patients aged ≥70 years.METHODSData of patients between December 2006 and January 2016 were retrospectively analyzed. In total, 66(4 females and 62 males) patients were evaluated for this analysis. The median age was 74 (range, 70–86years) years. The total RT dose was 70 Gy and 60–66 Gy for definitive and postoperative settings with 2Gy per fraction, respectively.RESULTSThe median follow-up time was 29.5 (range, 4–126 months) months. Using the tumor, node, metastasis(TNM) classification, tumors were stage IIA (18.2%), stage IIIA (31.8%), stage IIIB (3%), and stage IVA(47%). The purpose of RT was definitive for 33 (50%) patients and postoperative for 33 (50%) patients.Concomitant chemotherapy was used in 21 (31%) patients with 9 (42%) receiving cetuximab and 12(58%) receiving cisplatin. Cisplatin dose reduction was needed in 20% patients, but cetuximab was usedas per a suggested protocol. The 3-year local relapse free (LRF), metastases free (MF), and overall survival rates for all patients were 74%, 84%, and 48%, respectively. Only 26 (40%) patients died due todisease specific problems, and 18 (27%) patients died of unknown causes. In the toxicity evaluation, nograde 3–4 adverse effect was seen. Any type of cytopenia status was reported in 14 (21%) patients, andthis rate was statistically higher in concomitant radiochemotherapy group (p=003).CONCLUSIONRT seems to be an effective therapy in elderly population either alone or concomitant with chemotherapy in definitive and postoperative settings. In contrast, comorbid diseases should be managed carefullyin the treatment and follow-up periods.

PDF

___

1. United Nation-Population-Departments of Ecomonomic and Social Affairs-Population AGEING 2002. Available at: http://www.un.org/esa/population/publications/ageing/Graph.pdf. Accessed Dec 22, 2017.
2. Balducci L, Beghe’ C. Cancer and age in the USA. Crit Rev Oncol Hematol 2001;37(2):137–45.
3. Bernardi D, Barzan L, Franchin G, Cinelli R, Balestreri L, Tirelli U, et al. Treatment of head and neck cancer in elderly patients: state of the art and guidelines. Crit Rev Oncol Hematol 2005;53(1):71–80.
4. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65(1):5–29.
5. Muir CS, Fraumeni JF Jr, Doll R. The interpretation of time trends. Cancer Surv 1994;19-20:5–21.
6. Adelstein DJ, Li Y, Adams GL, Wagner H Jr, Kish JA, Ensley JF, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003;21(1):92–8.
7. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354(6):567–78.
8. Sobin LH, Gospodarowicz MK, Wittekind C. TNM Classification of malignant tumors. 7th ed. Available at: http://eu.wiley.com/WileyCDA/WileyTitle/productCd-1444332414.htlm. Accessed Dec 22, 2017.
9. Protocol Development. CTEP. Available at: http://ctep. cancer.gov/protocolDevelopment/electronic_applications/ctc.htlm. Accessed Dec 22, 2017.
10.Sarris EG, Harrington KJ, Saif MW, Syrigos KN. Multimodal treatment strategies for elderly patients with head and neck cancer. Cancer Treat Rev 2014;40(3):465–75.
11.Magrini SM, Buglione M, Corvò R, Pirtoli L, Paiar F, Ponticelli P, et al. Cetuximab and Radiotherapy Versus Cisplatin and Radiotherapy for Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial. J Clin Oncol 2016;34(5):427–35.
12.Ward MC, Reddy CA, Adelstein DJ, Koyfman SA. Use of systemic therapy with definitive radiotherapy for elderly patients with head and neck cancer: A National Cancer Data Base analysis. Cancer 2016 Aug 9 [Epub ahead of print], doi: 10.1002/cncr.30214.
13.Amini A, Jones BL, McDermott JD, Serracino HS, Jimeno A, Raben D, et al. Survival outcomes with concurrent chemoradiation for elderly patients with locally advanced head and neck cancer according to the National Cancer Data Base. Cancer 2016;122(10):1533–43.
14.Falk AT, Hébert C, Tran A, Chand ME, Leysalle A, Thariat J, et al. Radiotherapy for elderly patients and cetuximab, a monocentric study. Eur Arch Otorhinolaryngol 2017;274(2):1061–5.
15.Fowler JF, Lindstrom MJ. Loss of local control with prolongation in radiotherapy. Int J Radiat Oncol Biol Phys 1992;23(2):457–67.
16.Ho C. Cetuximab in locally advanced head-andneck cancer: defining the population. Curr Oncol 2010;17(4):48–51.
17.Kataria T, Gupta D, Bisht SS, Goyal S, Basu T, Srivastava A, et al. Chemoradiation in elderly patients with head and neck cancers: a single institution experience. Am J Otolaryngol 2015;36(2):117–21.